Cellbricks Therapeutics raises 10 million euros for bio-printed tissues

The biotech startup Cellbricks Therapeutics has raised fresh capital totaling around 10 million euros to further advance the development of living tissue implants. The financing comprises a seed round of 7 million euros and additional non-dilutive funds of more than 3 million euros, which are currently under negotiation.

The round was led by Silicon Roundabout Ventures. Other investors include SPRIND and existing investors such as ACT Venture Partners.

Focus on clinical application of living tissue

Cellbricks Therapeutics intends to use the capital to take the next step towards clinical application. The focus is on the preclinical validation of biofabricated, vascularized tissue implants.

Among other things, several preclinical animal studies are planned to provide crucial data for later application in humans. The aim is to demonstrate the functionality and integration of the artificially produced tissue in the body.

New approaches for wound healing and reconstruction

The immediate focus is on applications in reconstructive surgery, wound healing and trauma care. Existing therapies often reach their limits, particularly in the case of severe soft tissue injuries, burns or complex defects.

The company's leading development program focuses on implants made from adipose tissue, which are intended to serve as a biological alternative to synthetic implants, for example in breast reconstruction. The aim is to restore not only the shape but also the function of tissue.

Step-by-step path to bioprinted organs

In the long term, Cellbricks Therapeutics is pursuing the production of functional, bio-printed human organs. However, the path to this goal is a gradual one. First of all, key challenges in the areas of biology, engineering and clinical translation need to be solved. Living implants that survive, integrate and function in the body are seen as a crucial intermediate stage.

Proprietary biofabrication platform as the basis

The company has developed its own technology platform that can be used to produce vascularized human tissue. This makes it possible to produce complex tissue structures with blood vessels.

In parallel, Cellbricks Therapeutics is further expanding its activities in the innovation centers in Berlin and Boston in order to drive research, development and scaling internationally.

Transition from vision to validation

With the current funding, the company aims to make the transition from technological vision to clinical evidence. The focus is on generating reliable data and establishing a clear development perspective for use in humans.